Detalhe da pesquisa
1.
Combination carboplatin and nab-paclitaxel as a first-line treatment for advanced thymic carcinoma.
Invest New Drugs
; 41(1): 115-121, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36633784
2.
The Glasgow Prognostic Score Predicts Outcomes of Pembrolizumab or Atezolizumab Monotherapy in Patients with Pretreated Non-Small Cell Lung Cancer.
Oncology
; 101(1): 69-76, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36103811
3.
The Glasgow Prognostic Score Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations Who Are Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors.
Oncology
; 101(11): 685-694, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37166346
4.
First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study.
Invest New Drugs
; 40(2): 430-437, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34807331
5.
Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer.
Invest New Drugs
; 38(6): 1906-1914, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32415486
6.
Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations.
Oncology
; 95(2): 109-115, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29698957
7.
Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer.
BMC Cancer
; 16: 197, 2016 Mar 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26955807
8.
Comparison of the efficacy of gefitinib in patients with non-small cell lung cancer according to the type of epidermal growth factor receptor mutation.
Oncology
; 87(4): 215-23, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25034225
9.
Evaluation of amrubicin as a third or later line of chemotherapy for advanced non-small cell lung cancer.
Chemotherapy
; 59(2): 99-105, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24021914
10.
[A case of lung adenocarcinoma with coexisting G719X and T790M EGFR mutations in which erlotinib was effective for the treatment of leptomeningeal carcinomatosis].
Gan To Kagaku Ryoho
; 40(3): 375-7, 2013 Mar.
Artigo
em Japonês
| MEDLINE | ID: mdl-23507602
11.
[Efficacy of chemotherapy with carboplatin-paclitaxel plus bevacizumab for previously treated patients with advanced non-small cell carcinoma].
Gan To Kagaku Ryoho
; 39(13): 2509-12, 2012 Dec.
Artigo
em Japonês
| MEDLINE | ID: mdl-23235169
12.
Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data.
JTO Clin Res Rep
; 3(11): 100404, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36275911
13.
[Early diagnosis of metastatic spinal tumor is a key for effective palliative radiotherapy in patients with lung cancer].
Gan To Kagaku Ryoho
; 38 Suppl 1: 64-6, 2011 Dec.
Artigo
em Japonês
| MEDLINE | ID: mdl-22189323
14.
A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer.
Cancer Manag Res
; 13: 8695-8705, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34849025
15.
Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab.
Thorac Cancer
; 11(4): 1005-1014, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32057187
16.
Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer.
Cancer Manag Res
; 12: 4911-4921, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32606979
17.
Activity of Nivolumab and Utility of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study.
Clin Lung Cancer
; 20(3): 208-214.e2, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29803573
18.
Prognostic differences between oligometastatic and polymetastatic extensive disease-small cell lung cancer.
PLoS One
; 14(4): e0214599, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31002722
19.
Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: A prospective observational study.
Thorac Cancer
; 10(4): 880-889, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30821083
20.
Questionnaire survey on patient awareness of invasive rebiopsy in advanced non-small cell lung cancer.
Thorac Cancer
; 10(3): 501-507, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30648806